Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.56 |
| ▸ | PIP4K2C | Q8TBX8 | 11/20 | 0.51 |
| ▸ | PIP4K2A | P48426 | 10/20 | 0.50 |
| ▸ | PIP4K2B | P78356 | 2/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4204040 | 0.90 | TRPV1 (0.61) | TRPV1PIP4K2CPIP4K2APIP4K2B | |
| SCHEMBL4210234 | 0.89 | TRPV1 (0.66) | TRPV1PIP4K2CPIP4K2APIP4K2B | |
| SCHEMBL4200695 | 0.87 | TRPV1 (0.59) | TRPV1PIP4K2CPIP4K2APIP4K2BMKNK1 | |
| SCHEMBL4206750 | 0.87 | TRPV1 (0.53) | TRPV1PIP4K2CPIP4K2AMKNK1 | |
| SCHEMBL13375705 | 0.85 | MKNK1 (0.48) | TRPV1MKNK1 | |
| SCHEMBL13375702 | 0.84 | MKNK1 (0.48) | TRPV1MKNK1 | |
| SCHEMBL3117655 | 0.83 | TRPV1 (0.71) | TRPV1PIP4K2CPIP4K2APIP4K2B | |
| SCHEMBL4206894 | 0.83 | TRPV1 (0.66) | TRPV1MKNK1 | |
| SCHEMBL4202162 | 0.82 | TRPV1 (0.56) | TRPV1MKNK1 | |
| SCHEMBL14289495 | 0.80 | TRPV1 (0.70) | TRPV1PIP4K2CPIP4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160376291-A1 | IMIDAZOLO-, OXAZOLO-, AND THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-12-29 | — | — | US | claimed |
| EP-2224929-B1 | IMIDAZOLO-, OXAZOLO-, AND THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-05-04 | — | — | EP | claimed |
| US-20140107098-A1 | IMIDAZOLO-, OXAZOLO-, AND THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA NV (US) | 2014-04-17 | — | — | US | claimed |
| US-20130005687-A1 | IMIDAZOLO-, OXAZOLO-, AND THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 | BRANSTETTER BRYAN JAMES (US) | 2013-01-03 | — | — | US | claimed |
| US-8288397-B2 | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2012-10-16 | — | — | US | claimed |
| US-20090156599-A1 | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-18 | — | — | US | claimed |
| US-20160376291-A1 | IMIDAZOLO-, OXAZOLO-, AND THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-12-29 | — | — | US | disclosed |
| US-20160376291-A1 | IMIDAZOLO-, OXAZOLO-, AND THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-12-29 | — | — | US | disclosed |
| US-9440978-B2 | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-13 | — | — | US | disclosed |
| US-9440978-B2 | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-13 | — | — | US | disclosed |
| US-9440978-B2 | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-13 | — | — | US | disclosed |
| EP-2224929-B1 | IMIDAZOLO-, OXAZOLO-, AND THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-05-04 | — | — | EP | disclosed |
| EP-2224929-B1 | IMIDAZOLO-, OXAZOLO-, AND THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-05-04 | — | — | EP | disclosed |
| US-20130005687-A1 | IMIDAZOLO-, OXAZOLO-, AND THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 | BRANSTETTER BRYAN JAMES (US) | 2013-01-03 | — | — | US | disclosed |
| US-20130005687-A1 | IMIDAZOLO-, OXAZOLO-, AND THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 | BRANSTETTER BRYAN JAMES (US) | 2013-01-03 | — | — | US | disclosed |
| US-20130005687-A1 | IMIDAZOLO-, OXAZOLO-, AND THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 | BRANSTETTER BRYAN JAMES (US) | 2013-01-03 | — | — | US | disclosed |
| US-8288397-B2 | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2012-10-16 | — | — | US | disclosed |
| US-8288397-B2 | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2012-10-16 | — | — | US | disclosed |
| US-20090156599-A1 | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-18 | — | — | US | disclosed |
| US-20090156599-A1 | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376291-A1 | IMIDAZOLO-, OXAZOLO-, AND THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 | TRPV1, TRPA1, TRPV4 | TRPV1 1/4885PIP4K2C 714/4885PIP4K2A 800/4885 |
| US-20130005687-A1 | IMIDAZOLO-, OXAZOLO-, AND THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 | TRPV1, TRPA1, TRPV4 | TRPV1 1/4885PIP4K2C 714/4885PIP4K2A 800/4885 |
| US-20140107098-A1 | IMIDAZOLO-, OXAZOLO-, AND THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 | TRPV1, TRPA1, TRPV4 | TRPV1 1/4885PIP4K2C 714/4885PIP4K2A 800/4885 |
| US-20090156599-A1 | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 | TRPV1, TRPA1, TRPV4 | TRPV1 1/4885PIP4K2C 714/4885PIP4K2A 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.